larg
barrelshap
multisubunit
complex
harbour
sever
proteas
activ
substrat
thread
barrel
degrad
proteas
proteolysi
process
crucial
normal
turnov
protein
cell
proteas
involv
protein
destruct
also
activ
growth
cell
divis
differenti
migrat
signal
cellular
process
addit
mani
virus
use
cellular
viral
proteas
variou
purpos
activ
surfac
protein
membran
fusion
consequ
specif
proteas
inhibitor
attract
drug
candid
tabl
although
differ
specif
proteas
use
recent
year
assess
activ
vitro
action
difficult
determin
moreorless
physiolog
condit
proteas
divid
number
class
serin
aspart
cystein
threonin
metalloproteas
classif
scheme
basic
refer
amino
acid
metal
catalys
nucleophil
attack
substrat
peptid
bond
enzym
proteolyt
activ
frequent
evolv
carri
import
task
result
larg
diverg
famili
proteas
often
unrel
enzym
differ
mani
respect
one
characterist
unit
hydrolys
peptid
bond
therebi
cut
protein
small
piec
distinct
fragment
precis
chemic
reaction
allow
design
probe
select
monitor
proteas
activ
one
gener
recogn
function
proteas
recycl
protein
amino
acid
protein
singl
number
reason
includ
sign
malfunct
misfold
although
vast
major
protein
face
destruct
old
expir
substanti
fraction
newli
synthes
protein
undergo
similar
fate
possibl
fail
adopt
proper
conform
misfold
protein
tend
aggreg
rapid
recognit
degrad
aberr
protein
crucial
surviv
cell
moreov
mani
case
destruct
protein
crucial
correct
control
cellular
regulatori
switch
case
degrad
result
malfunct
fact
determin
specif
spatial
tempor
control
signal
event
rout
lead
fulllength
intracellular
protein
constitu
amino
acid
multistep
process
fig
first
process
degrad
protein
proteasom
gener
small
peptid
fragment
initi
cleavag
stage
gener
suffici
abolish
protein
function
activ
second
collect
proteas
among
tripeptidyl
peptidaseii
tppii
leucin
aminopeptidas
lap
thimet
oligopeptidas
top
trim
small
peptid
fragment
stepwis
singl
amino
acid
fluoresc
probe
proteolysi
tool
drug
discoveri
jacqu
neefj
nico
p
dantuma
cell
contain
numer
proteas
found
mani
differ
locat
proteas
recogn
even
larger
number
differ
substrat
involv
almost
everi
process
cell
aberr
proteolysi
link
plethora
diseas
cancer
inflamm
arteriosclerosi
neurodegener
infect
welldefin
chemistri
key
role
patholog
proteas
import
target
drug
develop
recent
progress
develop
fluoresc
probe
open
possibl
visual
proteas
activ
natur
environ
cell
describ
variou
strategi
follow
proteas
activ
cell
organ
complex
class
mhc
ubiquit
express
cellsurfac
glycoprotein
present
fragment
protein
immun
system
fragment
usual
compris
nine
amino
acid
gener
deriv
intracellular
protein
mhc
class
molecul
therebi
allow
immun
system
assay
intracellular
protein
content
includ
pathogen
domain
fold
function
independ
element
insert
modular
domain
protein
chang
behaviour
protein
accordingli
explain
ubiquitinproteasom
system
implic
larg
number
divers
patholog
exampl
aberr
proteasom
degrad
contribut
malign
transform
immun
system
reli
ubiquitinproteasom
system
gener
antigen
peptid
present
major
histocompat
complex
mhc
class
molecul
proteasom
also
crucial
role
inflammatori
respons
degrad
inhibitor
nuclear
given
function
surpris
proteasom
inhibitor
anticanc
antiinflammatori
angiostat
immunomodul
activ
recent
first
proteasom
inhibitor
bortezomib
velcad
millennium
boron
acid
inhibitor
tabl
fig
approv
success
clinic
trial
patient
suffer
multipl
myeloma
notabl
two
drug
affect
proteasom
degrad
use
patient
time
without
recogn
drug
human
immunodefici
viru
hiv
proteas
inhibitor
ritonavir
norvir
abbot
laboratori
saquinavir
fortovas
roch
recent
shown
affect
proteasom
activ
well
suggest
inhibit
proteasom
compound
could
account
increas
hyperlipidaemia
reduc
incid
kaposi
sarcoma
patient
treat
drug
moreov
inhibitor
radiosensit
tumour
cell
ioniz
radiat
block
proteasom
specif
proteasom
inhibitor
peptid
aldehyd
boron
acid
vinyl
sulfon
epoxyketon
use
mani
year
laboratori
fig
wherea
drug
target
proteasom
rel
new
unexplor
proteasom
inhibitor
modul
hold
great
promis
potenti
drug
multipl
disord
past
year
sever
group
develop
fluoresc
probe
ubiquitinproteasom
system
behav
authent
protein
substrat
fig
protein
specif
recruit
proteasom
subsequ
unfold
thread
core
degrad
complex
proteasom
gener
recogn
substrat
presenc
polyubiquitin
chain
conjug
intern
lysin
residu
substrat
less
commonli
conjug
free
amino
terminu
substrat
protein
modifi
addit
polyubiquitin
chain
specif
ubiquityl
enzym
physic
interact
degrad
signal
misfold
domain
small
motif
posttransl
modif
detect
substrat
crucial
observ
regard
protein
process
degrad
signal
target
protein
ubiquityl
proteasom
degrad
behav
modular
domain
domain
often
function
transfer
protein
identif
fluoresc
protein
jellyfish
soft
coral
possibl
emerg
use
fluoresc
protein
substrat
resembl
authent
protein
substrat
proteasom
instead
small
fluoresc
peptid
commonli
use
vitro
assay
reus
synthesi
new
protein
endocytos
protein
usual
enter
cytoplasm
instead
direct
lysosom
compart
fig
lysosom
anoth
group
proteas
cathepsin
degrad
intern
protein
piec
fragment
subsequ
reduc
singl
amino
acid
lysosom
aminopeptidas
like
tppi
dipeptidyl
peptidaseii
dppii
given
broad
substrat
specif
proteasom
cathepsin
proteas
compartment
prevent
random
degrad
innoc
bystand
achiev
place
activ
site
proteas
within
larg
multisubunit
complex
case
proteasom
within
lysosom
case
cathepsin
addit
broadli
act
proteas
proteas
involv
mani
specif
process
blood
clot
apoptosi
extracellular
matrix
degrad
cleavag
transmembran
protein
precursor
process
secretori
pathway
clearli
proteas
destroy
protein
also
convert
protein
activ
moieti
addit
proteolyt
cascad
regul
import
cellular
switch
therefor
surpris
proteas
get
lot
scientif
attent
recent
literatur
search
reveal
roughli
paper
publish
proteas
past
year
yet
anoth
one
one
describ
time
issu
proteas
activ
monitor
vivo
given
chemistri
proteas
variou
fluoresc
substrat
design
past
year
test
activ
well
effect
drugmedi
inhibit
system
cell
anim
understand
physiolog
proteolyt
process
insid
live
organ
crucial
import
assess
role
proteas
diseas
develop
drug
target
system
ubiquitinproteasom
system
import
regul
cell
cycl
induct
apoptosi
degrad
key
regulatori
molecul
addit
proteolyt
system
respons
keep
cell
free
misfold
protein
import
function
anoth
report
substrat
gener
help
degrad
signal
introduct
small
motif
convert
gfp
shortliv
proteasom
substrat
fig
noteworthi
motif
origin
identifi
random
yeast
screen
protein
target
ubiquityl
enzym
engag
endoplasm
reticulum
er
associ
degrad
erad
erad
pathway
use
aberr
er
protein
releas
er
access
cytosol
proteasom
degrad
mhc
class
molecul
convert
genuin
erderiv
substrat
ubiquitinproteasom
system
sever
virus
frustrat
antigen
present
target
mhc
class
molecul
exampl
human
cytomegaloviru
hcmv
protein
bind
mhc
class
molecul
er
disloc
cytosol
first
set
fluoresc
report
gener
ubiquitinproteasom
system
nend
rule
ubiquitin
fusion
degrad
ufd
signal
fuse
green
fluoresc
protein
gfp
degrad
signal
origin
identifi
varshavski
cowork
accord
nend
rule
ident
ntermin
aminoacid
residu
use
time
degrad
protein
ubiquitinproteasomedepend
proteolysi
fig
case
ufd
substrat
ntermin
ubiquitin
moieti
fuse
gfp
open
read
frame
function
acceptor
polyubiquitin
chain
fig
stack
cowork
show
insert
multipl
ufd
signal
could
acceler
protein
turnov
facilit
degrad
altern
report
luciferas
remain
stabl
insert
singl
ufd
signal
fluorigen
peptid
substrat
function
statu
ubiquitinproteasom
system
gfp
report
reveal
cell
contain
larg
excess
proteasom
activ
probabl
requir
instantli
clear
misfold
protein
stress
condit
ufdgfp
report
also
use
studi
individu
contribut
proteolyt
activ
site
proteasom
protein
degrad
ufd
nend
rule
gfp
substrat
use
analys
effect
protein
domain
proteasom
turnov
simpl
insert
domain
report
substrat
approach
use
detail
studi
viral
repetit
sequenc
expand
polyglutamin
repeat
caus
factor
number
neurodegen
disord
two
repetit
sequenc
previous
shown
affect
proteasom
degrad
present
report
substrat
exploit
identif
socal
stabil
signal
signal
enabl
protein
resist
proteasom
degrad
heessen
g
masucci
n
p
unpublish
result
anoth
conveni
aspect
use
protein
substrat
report
oppos
peptid
substrat
readili
appli
gener
transgen
anim
notabl
express
gfp
well
toler
mice
although
side
effect
report
specif
model
recent
first
transgen
mous
model
ubiquitinproteasom
system
gener
ubiquit
express
ufdgfp
report
anticip
tissu
mice
emit
gfp
fluoresc
despit
presenc
reporterencod
transcript
tissu
analys
inject
proteasom
inhibitor
mice
result
dramat
increas
fluoresc
intens
affect
tissu
anoth
anim
model
ufd
bioluminesc
reporterexpress
human
cell
line
implant
nude
mice
human
cell
respond
dosedepend
increas
bioluminesc
administr
proteasom
inhibitor
bortezomib
mice
particular
transgen
mous
model
open
new
dimens
studi
ubiquitinproteasom
system
patholog
ubiquit
express
long
suspect
impair
ubiquitinproteasom
system
contribut
mani
neurodegen
diseas
conform
disord
although
confirm
cellular
system
diseaseassoci
protein
inde
affect
ubiquitinproteasom
system
experiment
approach
mean
reflect
complex
patholog
neurodegen
diseas
report
mous
model
use
conjunct
excel
mous
model
avail
studi
disord
assess
function
ubiquitinproteasom
system
diseas
progress
emphas
howev
impair
ubiquitinproteasom
system
one
mani
model
put
forward
explan
rapidli
degrad
ubiquitinproteasom
system
coexpress
hcmv
protein
ntermin
gfptag
mhc
class
human
cell
result
function
report
system
proteasom
degrad
er
protein
fig
administr
proteasom
inhibitor
reporterexpress
cell
stabil
gfp
report
result
increas
fluoresc
intens
fact
fluoresc
protein
follow
pathway
endogen
substrat
allow
function
analysi
ubiquitinproteasom
system
cell
inde
accumul
ufd
substrat
respons
administr
proteasom
inhibitor
shown
correl
cellcycl
arrest
apoptosi
consequ
gener
blockag
proteasom
degrad
evalu
effect
drug
counteract
effect
impair
ubiquitinproteasom
system
diseas
patholog
observ
conform
disord
yet
model
hold
true
cross
gfpreport
mice
diseas
model
mice
also
use
peptid
effici
absorb
emit
light
fl
group
unless
two
group
separ
fig
use
moreorless
standard
peptid
chemistri
substrat
synthes
defin
question
relat
peptid
degrad
live
cell
peptid
diffus
across
membran
therefor
introduc
live
cell
microinject
detail
analysi
realtim
degrad
peptid
live
cell
reveal
peptid
short
halflif
sever
second
sole
result
aminopeptidas
activ
peptidas
crucial
trim
peptid
correct
size
mhc
class
antigen
present
howev
individu
contribut
peptidas
total
intracellular
peptidas
activ
cell
unclear
studi
specif
inhibitor
show
proteasom
contribut
digest
small
peptid
live
cell
even
though
vitro
peptid
degrad
readili
measur
use
peptid
degrad
monitor
use
chemic
fluorophor
strategi
detect
peptidas
activ
live
cell
use
peptid
contain
fluoresc
reson
energi
transfer
fret
fluorophor
pair
fig
fret
oper
detect
fluorophor
apart
therefor
spatial
separ
two
fluorophor
result
proteas
activ
easili
assay
result
increas
emiss
donor
fluorophor
expens
emiss
acceptor
fluorophor
strategi
use
peptid
contain
fluorescein
fl
group
tetramethylrhodamin
tmr
group
separ
six
amino
acid
energi
transfer
fl
tmr
occur
intact
peptid
lost
peptid
separ
result
degrad
dramat
differ
observ
instead
tmr
quencher
molecul
use
anoth
import
class
drug
target
mediat
breakdown
extracellular
matrix
extracellular
matrix
metalloproteas
mmp
larg
famili
metalloproteas
present
cell
surfac
extracellular
space
mmp
recogn
drug
target
cancer
treatment
metastat
cell
degrad
extracellular
matrix
angiogenesi
invas
tissu
sever
mmp
inhibitor
marimastat
british
biotech
tanomastat
bayer
tabl
develop
test
clinic
trial
although
clinic
trial
without
success
live
high
expect
compound
still
ampl
reason
believ
specif
drug
earli
interfer
tumour
progress
might
improv
efficaci
weissled
cowork
develop
nearinfrar
fluoresc
nirf
peptid
substrat
use
vivo
monitor
cathepsin
activ
use
synthet
nontox
nonimmunogen
copolym
previous
test
clinic
trial
compos
polylysin
backbon
stabil
conjug
multipl
polyethylen
glycol
side
chain
fluorophor
coupl
high
densiti
backbon
ident
fluorophor
interfer
increas
relax
time
excit
similar
normal
fret
pair
fig
although
mechan
fulli
understood
result
quench
unless
fluorophor
dilut
degrad
inde
found
emiss
signal
effici
quench
intact
copolym
render
almost
nonfluoresc
wherea
vitro
cleavag
probe
consider
increas
emit
light
measur
fluoresc
live
anim
dye
use
excit
nearinfrar
light
long
wavelength
hardli
scatter
absorb
tissu
nirf
probe
expect
function
gener
molecular
probe
lysosom
proteas
abl
cleav
polylysin
backbon
activ
probe
could
follow
cell
inhibitor
experi
confirm
lysosom
cystein
serin
proteas
primarili
respons
activ
nirf
report
cell
line
use
xenotransplant
human
tumour
nude
mice
shown
nirf
probe
predominantli
taken
activ
tumour
tissu
possibl
consequ
rel
permeabl
neovasculatur
noninvas
nearinfrar
reflect
imag
techniqu
small
tumour
contain
cleav
nirf
probe
could
identifi
maxim
tissu
depth
cm
nirf
report
also
use
studi
role
cathepsin
b
atherosclerosi
administr
intraven
cathepsin
b
activ
found
upregul
lesion
mous
model
atherosclerosi
nirf
tomograph
imag
allow
threedimension
imag
probe
deeper
tissu
could
local
lesion
aortic
arch
mice
sole
presenc
activ
nirf
report
standard
method
quantifi
proteasom
activ
crucial
role
peptid
degrad
found
tppii
although
aminopeptidas
remov
ntermin
sequenc
usual
one
three
amino
acid
peptid
substrat
tppii
abl
remov
longer
fragment
includ
fragment
mhc
class
e
reit
j
n
unpublish
result
along
similar
line
rna
interfer
rnai
defin
peptidas
might
reveal
contribut
specif
peptidas
total
cellular
peptidas
activ
although
small
quench
peptid
substrat
proven
valuabl
tool
studi
proteas
purifi
sampl
vitro
cell
line
microinject
fact
cross
membran
limit
applic
monitor
intracellular
proteolysi
vivo
howev
proteas
activ
cell
surfac
endosomallysosom
compart
major
limit
cystein
serin
aspart
proteas
present
lysosom
implic
mani
cellular
process
lysosom
cathepsin
essenti
turnov
protein
reach
lysosom
compart
extracellular
space
endocytosi
secretori
pathway
sort
cytosol
autophagi
subtl
regulatori
function
mhc
class
ii
antigen
present
lysosom
proteas
believ
involv
diseas
cancer
inflamm
autoimmun
disord
atherosclerosi
sever
genet
disord
shown
proteas
particip
destruct
extracellular
matrix
surround
tumour
import
prerequisit
tumour
invas
metastasi
angiogenesi
howev
cathepsin
import
role
lysosom
protein
turnov
caution
taken
inhibit
enzym
impair
cathepsin
result
lysosom
storag
diseas
special
lysosom
proteas
cathepsin
express
immun
system
assist
mhc
class
ii
antigen
present
also
import
drug
target
fact
select
inhibitor
cathepsin
develop
shown
prevent
autoimmun
respons
mous
model
syndrom
tabl
fret
physic
phenomenon
energi
transfer
donor
acceptor
fluorophor
possibl
donoracceptor
pair
separ
short
distanc
usual
onequart
less
light
wavelength
use
excit
donor
fluorophor
act
short
distanc
principl
energi
transfer
emiss
photon
captur
acceptor
fluorophor
mere
electromagnet
energi
transfer
result
dipol
moment
fret
effici
highli
depend
distanc
decay
distanc
formul
forster
law
make
fret
highli
suitabl
detect
conform
chang
protein
distanc
donor
acceptor
chang
degrad
donor
acceptor
pair
separ
cleavag
substrat
addit
rel
orient
fluorophor
determin
fret
socal
orient
factor
usual
unknown
prevent
determin
real
distanc
basi
fret
data
fretbas
probe
develop
caspas
famili
relat
cystein
proteas
involv
execut
apoptosi
enzym
activ
proteolyt
cascad
reaction
tightli
control
caspas
divid
two
group
initi
caspas
set
cascad
activ
caspas
effector
caspas
cleav
multipl
cellular
substrat
destroy
cellular
protein
content
apoptosi
key
factor
mani
diseas
process
includ
neuron
loss
excess
apoptosi
neurodegen
disord
escap
apoptosi
cancer
caspas
induc
well
executor
cell
death
potenti
drug
target
evid
tabl
xu
cowork
gener
first
function
caspas
fret
probe
basi
fluoresc
protein
insert
small
peptid
target
sequenc
effector
gfp
blue
fluoresc
protein
bfp
fig
induct
apoptosi
cell
express
fusion
protein
result
loss
fret
signal
bfp
donor
gfp
acceptor
consequ
activ
major
drawback
bfpgfp
fret
pair
bfp
donor
excit
ultraviolet
light
caus
consider
cellular
damag
therefor
far
optim
studi
live
cell
sever
new
spectral
variant
base
modifi
gfp
fluoresc
protein
sourc
gener
past
year
ultraviolet
excit
avoid
recent
fret
probe
cyan
fluoresc
protein
cfp
yellow
fluoresc
protein
yfp
combin
fig
chang
connect
peptid
sequenc
cfpyfp
combin
fret
probe
convert
probe
specif
initi
ref
studi
anoth
advantag
modular
composit
fret
probe
exploit
instead
introduc
small
cleavag
site
larger
protein
fragment
insert
probe
basic
compos
three
independ
modular
domain
report
target
domain
death
agonist
bid
use
gener
function
yfpbidcfp
report
fig
unfortun
fret
probe
contain
cfp
bfp
variant
limit
sensit
due
rel
poor
quantum
yield
variant
recent
report
construct
combin
gfp
yfp
suffer
limit
fig
optic
filter
separ
larg
overlap
excit
emiss
spectra
protein
therefor
energi
transfer
difficult
quantifi
sensit
emiss
fret
altern
quantit
method
fluoresc
lifetim
imag
microscopi
flim
measur
energi
transfer
probe
overlap
even
ident
spectra
flim
measur
effect
two
close
locat
fluorophor
relax
time
donor
acceptor
consequ
fret
like
fret
flim
decay
rapidli
distanc
detect
fluorophor
within
one
anoth
use
puls
light
sourc
chang
relax
time
determin
although
energi
lysin
composit
copolym
import
vivo
stabil
probe
specif
chang
modifi
aminoacid
sequenc
copolym
instead
strategi
use
fluorophor
connect
copolym
backbon
peptid
stalk
conjug
isopeptid
linkag
lysin
backbon
chang
aminoacid
sequenc
peptid
stalk
proteas
cleavag
site
probe
could
convert
substrat
specif
proteas
without
lose
vivo
stabil
approach
specif
nirf
report
gener
cathepsin
ref
vivo
imag
tumourbear
mice
probe
administr
could
use
discrimin
tumour
express
low
high
level
select
proteas
recent
similar
probe
use
imag
lymph
node
live
mice
report
help
detail
evalu
effect
potenti
drug
lysosom
extracellular
proteas
vivo
might
also
aid
earli
diagnosi
tumour
atherosclerot
lesion
least
imag
techniqu
allow
visual
probe
deep
tissu
realiti
substrat
cathepsin
mmp
peptid
fulllength
protein
shown
protein
substrat
label
highdens
fluorophor
also
use
studi
activ
lysosom
proteas
cell
line
although
seem
unlik
type
protein
use
anim
import
inform
combin
action
tumour
cell
toward
extracellular
protein
deduc
cell
cultur
system
sinc
introduct
recombin
dna
technolog
mani
report
substrat
proteas
gener
introduct
proteas
cleavag
site
protein
easili
detect
enzym
activ
proteolyt
cleavag
design
substrat
inactiv
enzymat
activ
form
reliabl
quantit
readout
proteas
activ
seem
tempt
appli
approach
gfp
fluoresc
protein
unfortun
present
avail
fluoresc
protein
well
suit
purpos
although
present
avail
fluoresc
protein
allow
gener
kind
nand
ctermin
fusion
protein
tightli
interwoven
structur
allow
major
modif
within
gfp
open
read
frame
gener
result
complet
loss
fluoresc
instead
research
turn
toward
fret
techniqu
describ
becam
possibl
develop
spectral
gfp
variant
fig
posit
proteas
cleavag
site
two
fluoresc
protein
variant
overlap
emiss
donor
excit
spectra
acceptor
fretbas
probe
proteas
gener
use
gfp
variant
instead
dye
enabl
construct
proteas
substrat
requir
vitro
modif
therefor
directli
express
target
cell
organ
sever
effici
fluorescencebas
much
energi
emit
energi
absorb
fluorophor
caspas
cleavag
site
posit
directli
variabl
nterminu
gfp
fusion
caspas
cleav
origin
nterminu
report
gener
new
one
fate
gfp
protein
switch
effici
nend
rule
proteasom
substrat
inher
stabl
gfp
protein
vice
versa
depend
amino
acid
flank
cleavag
site
stabil
destabil
gfp
report
consequ
caspas
activ
could
quantifi
live
cell
flow
cytometr
fluorimetr
analys
report
requir
singl
fluoresc
protein
give
readout
simpl
decreas
increas
gfp
fluoresc
two
characterist
make
favour
use
highthroughput
drug
screen
howev
one
inher
problem
compound
interfer
ubiquitinproteasom
system
affect
stabil
report
well
mani
infecti
pathogen
depend
proteas
surviv
virus
often
requir
viral
encod
proteas
process
precursor
protein
import
variou
step
viral
life
cycl
viral
proteas
import
target
develop
antivir
drug
genom
encod
aspart
proteas
essenti
gener
infecti
viru
particl
develop
drug
target
proteas
success
endeavour
result
drug
ritonavir
saquinavir
indinavir
crixivan
merck
nelfinavir
viracept
agouronpf
lopinavir
kaletra
abbot
laboratori
tabl
proteas
inhibitor
routin
use
part
highli
activ
antiretrovir
therapi
haart
regim
effici
control
hiv
replic
patient
haart
success
suppress
erad
viru
patient
ongo
viral
replic
often
result
emerg
inhibitorresist
viral
strain
therefor
need
novel
proteas
inhibitor
well
diagnost
test
identifi
anticip
inhibitorresist
strain
proteas
gener
autocatalyt
event
larg
precursor
protein
presenc
proteas
toxic
cell
surpris
consid
proteas
broad
specif
cleav
mani
cellular
substrat
two
consider
taken
account
design
gfpbase
report
proteas
first
proteas
must
releas
precursor
becom
fulli
activ
second
presenc
fulli
activ
proteas
toxic
cell
gener
artifici
precursor
compos
gfp
proteas
simpl
robust
report
made
base
two
characterist
transient
transfect
cell
plasmid
encod
nontox
proteas
construct
typic
result
low
gfp
level
cell
express
precursor
die
presenc
process
fulli
activ
proteas
administr
differ
inhibitor
cell
transfect
report
result
dosedepend
increas
gfp
fluoresc
due
accumul
unprocess
nontox
proteas
precursor
noninfecti
model
transfer
might
reliabl
determin
flim
spatiotempor
resolut
consider
less
achiev
fret
due
longer
sampl
time
applic
fluoresc
protein
fret
report
limit
caspas
although
caspas
studi
provid
proof
principl
similar
probe
feasibl
virtual
everi
proteas
specif
target
sequenc
posit
two
fluoresc
protein
variant
fact
core
fluoresc
protein
gener
modifi
probe
proteas
limit
design
report
modular
construct
fluoresc
protein
present
function
domain
besid
report
ubiquitinproteasom
system
fluoresc
protein
provid
degrad
signal
lead
process
degrad
fret
flimbas
caspas
report
assay
develop
use
differ
concept
lee
cowork
adapt
nend
rule
gfp
report
ubiquitinproteasom
system
probe
caspas
activ
report
gener
howev
unlik
report
method
visual
pool
intracellular
peptid
rather
activ
select
proteas
understand
mechan
proteolysi
effect
inhibitor
vivo
varieti
fluorescencebas
assay
develop
assay
allow
detect
proteas
activ
live
cell
help
us
elucid
individu
role
proteas
complex
proteolyt
system
live
cell
assay
use
monitor
effect
chemic
inhibitor
proteas
activ
select
downregul
proteas
rnai
interest
differ
follow
vivo
degrad
design
substrat
compar
vitro
assay
purifi
compon
design
substrat
analog
genuin
substrat
subject
multipl
cleavag
event
exampl
shown
degrad
gfpbase
substrat
ubiquitinproteasom
system
also
influenc
inhibitor
unrel
serin
proteas
appar
directli
indirectli
involv
proteolyt
system
fret
caspas
report
nirf
cathepsin
report
also
subject
cleavag
sever
caspas
although
might
complic
interpret
cleavag
event
reflect
vivo
situat
substrat
might
aid
identif
novel
proteas
unanticip
connect
proteolyt
system
complex
proteolysi
contribut
individu
proteas
total
proteas
activ
fulli
appreci
live
cell
even
better
vivo
recent
gener
gfpreport
mice
allow
monitor
proteasom
activ
effect
proteasom
inhibitor
vivo
expect
transgen
mice
express
fluoresc
proteinbas
report
system
follow
aid
develop
compound
target
proteas
develop
diagnost
assay
analysi
inhibitor
resist
viru
strain
inde
experi
character
mutant
proteas
patient
materi
show
probe
identifi
inhibitorresist
proteas
uhlikova
n
p
k
lindsten
g
masucci
j
konvalinka
unpublish
result
proteas
inhibitor
exemplifi
success
approach
target
viral
proteas
present
much
effort
put
develop
similar
compound
inhibit
proteas
lifethreaten
virus
proteas
hepat
c
viru
reit
cowork
use
indirect
approach
monitor
intracellular
protein
degrad
live
cell
follow
activ
peptid
transport
involv
antigen
present
mhc
class
molecul
show
gfptag
transport
associ
antigen
process
tap
could
use
indirectli
monitor
gener
small
peptid
fragment
intracellular
proteas
use
fluoresc
recoveri
photobleach
frap
techniqu
visual
tap
diffus
er
membran
shown
tap
diffus
rapidli
inact
slowli
process
pump
peptid
differ
mobil
probabl
reflect
differ
shape
radiu
predict
modif
einsteinstock
formula
diffus
correl
ln
r
radiu
protein
membran
record
mobil
tap
live
cell
use
show
larg
portion
peptid
gener
protein
immedi
degrad
translat
visual
contribut
influenza
infect
intracellular
peptid
pool
visual
effect
intracellular
peptid
degrad
e
reit
j
n
unpublish
result
disadvantag
techniqu
rather
complic
transport
associ
antigen
process
tap
special
heterodimer
atpbind
cassett
transport
er
peptid
transfer
er
lumen
peptid
bind
mhc
class
molecul
tap
also
associ
dedic
chaperon
call
tapasin
recruit
mhc
class
molecul
peptid
load
complex
call
mhc
class
load
complex
